29 results about "Positron Emission Tomography Scan" patented technology

The present disclosure sets forth novel compounds and compositions including heteroaromatic silicon-fluoride-acceptors, which are useful for PET scanning. The present disclosure further includes novel methods of 18F imaging for PET scanning, the methods comprising the preparation of conjugates and bioconjugates of biological ligands of interest with heteroaromatic silicon-fluoride-acceptors. In certain embodiments the invention is practiced in the form of a kit.

The embodiment of the invention provides an image processing system and method. The method may include acquiring first positron emission tomography (PET) data and second positron emission tomography (PET) data of an object. The first PET data is collected by performing a first PET scan and the second PET data is collected by performing a second PET scan. The method may include determining first reference data related to a first target event occurring in a first PET scan based on first PET data. The first target event includes at least a first backscatter event. The method may include determining, based on the second PET data, second reference data related to a second target event occurring in the second PET scan. The second target event includes at least a second backscatter event. The method may also include determining a motion vector field based on the first reference data and the second reference data.

A F-18 positron diagnostic contrast agent precursor, the F-18 positron diagnostic contrast agent prepared using the F-18 positron diagnostic contrast agent precursor can be used for positron emission tomography to detect type II vesicular monoamine transporter, produce no metabolites similar to F-18-propanol because the F-18 is marked on the aromatic ring, and can reduce the background value of normal organs while using.

The present disclosure provides a method that may include determining a first tumor mask corresponding to a first positron emission tomography (PET) scan and a first computed tomography (CT) scan present in the first PET scan and the first CT scan based on the first PET scan and the first CT scan from a first point in time. A second tumor mask corresponding to a second lesion present in a second PET scan and a second CT scan may be determined based on the second PET scan and the second CT scan from a second point in time. A longitudinal segmentation model may be applied to update each of the first tumor mask and the second tumor mask based on the first PET scan, the first CT scan, the second PET scan, and the second CT scan. A response to treatment for the disease may be determined based on at least one of the first updated tumor mask and the second updated tumor mask. Related systems and computer program products are also provided.

A method for safe radioisotope preparation and injection of H215O for use in Positron Emission Tomography (PET). The disclosure also relates to a safety valve for controlling a flow of H215O for use in PET, to a use of said safety valve and to a method for preparing and injecting H215O.

The present invention provides a closed loop generation and / or infusion system comprising a radionuclide generator, an activity detector, a controller, a dose calibrator, a pump, eluant source and an automated elution system controlled by software and hardware for generation and infusion of a radionuclide for administering a dose of generated radionuclide into a subject for diagnosing a peripheral arterial disease in a subject suffering from or suspected of suffering from peripheral arterial disease and / or metabolic disease via Positron Emitting Tomography (PET) or Single-photon emission computed tomography (SPECT) imaging technologies. More particularly, the present invention provides methods of determining whether a subject is suffering or at a risk of developing a peripheral arterial disease by performing quantitative assessment of blood flow in lower extremities or limbs of the subject; wherein the quantitative assessment is performed by analyzing one or more images and providing a severity score; and wherein the analysis of the one or more images is performed by using an automated system.

To provide compounds useful for imaging granzyme B by using medical imaging including positron tomography.SOLUTION: A method for imaging granzyme B in a cell or a tissue includes: i) a step of bringing a sample of the cell or tissue in contact with a compound of formula I or a pharmaceutically acceptable salt thereof; and ii) a step of imaging the cell or tissue by an appropriate imaging method and thus imaging granzyme B in the cell or tissue. In the formula, A includes one or a plurality of imaging agents, B denotes an arbitrary selected linking group, and C denotes a group binding to granzyme B.SELECTED DRAWING: None

The disclosure relates to a device and positron emission tomography (PET) scanner for acquiring a PET image and a system for generating the PET image. The disclosure describes a device that may have one or more moveable portions. The device may comprise an upper portion and a lower portion. The upper portion and lower portion define a cavity for a patient. At least one of the upper portion or the lower portion may be movable. The upper and lower portions may comprise a cap and wings, respectively, At least one of the caps and / or wings may comprise one or more detection modules. The wings may also move with respect to a corresponding cap.

A system for safe radioisotope preparation and injection of H215O for use in Positron Emission Tomography (PET). The invention also relates to a safety valve for controlling a flow of H215O for use in PET, to a use of said safety valve and to a method for preparing and injecting H215O.

The present disclosure relates to an [¹⁸F]-labeled imidazopyridine derivative or a salt thereof, as a positron emission tomography (PET) radiotracer, which is suitable for imaging of the stress signal non-receptor tyrosine kinase c-abl, and its use in in vivo diagnosis, pre-clinical and clinical imaging, patient stratification based on the c-abl mutation status, and assessment of response to treatment. The present disclosure also relates to the use of an [¹⁸F]-labeled imidazopyridine derivative as a PET radiotracer. The present disclosure also provides a method for radiosynthesizing an [¹⁸F]-labeled imidazopyridine derivative.

Radiolabeled compounds and methods of use thereof of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: R1 is a C1-C6 alkyl; R2 is H, a C1-C6 alkyl, or a C1-C6 haloalkyl; or R1 and R2 together form a 5- or 6-membered cycloalkyl ring, a substituted or unsubstituted thiophenyl, or a substituted or unsubstituted phenyl; R3 is H, a C1-C6 alkyl, a C1-C6 haloalkyl, a C1-C6 hydroxyl alkyl, a C3-C6 cycloalkyl, a C1-C6 alkylnitrile, or an C1-C6 alkylcycloalkyl; R4 is alkyl or haloalkyl; R5 is H or halide; and L is a 2 to 10 carbon linking group; provided that: when R1 is Me, R2 is Me, R3 is H, R4 is —OCH2CF3, and L is —CH2—CH2—CH2—, R5 is not H; and when R1 is Me, R2 is H, R3 is H, R4 is —OCH2CF3, and L is —CH2—CH2—CH2—, R5 is not H.

A method may include receiving a positron emission tomography (PET) scan depicting a plurality of cancer cells. One or more lesions depicted in the positron emission tomography (PET) scan can be identified. A provenance cell classification model can be applied to determine provenance cells for each lesion depicted in the positron emission tomography (PET) scan. A molecular subtype profile for the plurality of cancer cells depicted in positron emission tomography (PET) can be determined based at least on origin cells of a single lesion depicted in the positron emission tomography (PET) scan. The molecular subtype profile can include overall origin cells of the plurality of cancer cells and / or proportions of lesions with each possible origin cell. Related systems and computer program products are also provided.

The invention provides a < 68 > Ga-labeled small molecule compound as well as a preparation method and application thereof, and belongs to the technical field of radiopharmaceuticals and nuclear medicine. The [68Ga] Ga-DTPA-EOB probe marked by 68Ga is suitable for positron emission tomography, has better temporal-spatial resolution and dynamic imaging capability, and can quantify tracer distribution. Under the condition that the pH value of the < 68 > Ga is 3.8-4.0, < 68 > Ga labeling can be completed only within 5-10 minutes at room temperature, the labeling efficiency is high (the labeling rate is greater than or equal to 95%), and the amount of EOB-DTPA required for labeling is extremely small. The radioactive activity needed by PET imaging is low, the radiation burden on a patient is small, and the gadolinium deposition risk is avoided. The [68Ga] Ga-DTPA-EOB probe is particularly suited for scenes requiring rapid diagnosis, avoiding MRI contraindications, or requiring multi-modal imaging.

A method may include receiving a positron emission tomography (PET) scan depicting a plurality of cancerous cells. One or more lesions depicted in the positron emission tomography (PET) scan may be identified. A cell-of-origin classification model may be applied to determine a cell-of-origin of each lesion depicted in the positron emission tomography (PET) scan. A molecular subtype profile for the plurality of cancerous cells depicted in the positron emission tomography (PET) may be determined based at least on the cell-of-origin of the individual lesions depicted in the positron emission tomography (PET) scan. The molecular subtype profile may include an overall cell-of-origin of the plurality of cancerous cells and / or a proportion of lesions having each possible cell-of-origin. Related systems and computer program products are also provided.

Systems and methods of PET attenuation correction using low-field MR image data includes receiving a first set of image data and a set of low-field magnetic resonance (MR) image data. An attenuation correction map is generated from the low-field MR image data using a first trained neural network. At least one attenuation correction process is applied to the first set of image data based on the attenuation correction map to generate at least one clinical attenuation-corrected image.

Systems and methods for image processing are provided. The methods may include obtaining first positron emission tomography (PET) data and second PET data of a subject. The methods may include determining, based on the first PET data, first reference data relating to first target events occurred in the first PET scan. The first target events at least include first backscatter events. The methods may include determining, based on the second PET data, second reference data relating to second target events occurred in the second PET scan. The second target events at least include second backscatter events. The methods may further include determining a motion vector field based on the first reference data and the second reference data.

The method may include receiving a positron emission tomography (PET) scan depicting multiple cancer cells. One or more lesions depicted in the PET scan may be identified. An origin cell classification model may be applied to determine the origin cells of each lesion depicted in the PET scan. A molecular subtype profile of multiple cancer cells depicted in the PET scan may be determined based on the origin cells of at least the individual lesions depicted in the PET scan. The molecular subtype profile may include the overall origin cells of the multiple cancer cells and / or the proportion of lesions having each possible origin cell. Related systems and computer program products are also provided.

The present invention relates to novel, selective, radiolabelled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

A method and system are provided for combining a three-dimensional positron emission tomography (PET) scan and a three-dimensional computed tomography (CT) scan of a body into a combined three-dimensional image for the training and application of a machine learning model for the segmentation of an organ or anatomical structure. The method includes co-registering each of the PET scan and the CT scan as an input scan with reference to a reference scan in the form of the other of the PET scan or CT scan, or in the form of a third image for outputting a co- registered PET scan and a co-registered CT scan. The method including combining the co- registered PET scan and the co-registered CT scan with a PET bias factor weight and a CT bias factor weight with a selected bias factor favouring the PET scan to produce a combined PET and CT scan.

The utility model provides a supporting structure of medical equipment and a positron emission tomography assembly, the positron emission tomography assembly comprises a plurality of PET units and a plurality of supporting structures of the medical equipment, the supporting structures of all the medical equipment are sequentially spliced in the first direction, and all the PET units are installed on the supporting structures of all the medical equipment respectively. The supporting structure of the medical equipment comprises a base, a first splicing part and a second splicing part are arranged at the two opposite ends of the base in the first direction respectively, the first splicing part is used for being connected with the second splicing part of the adjacent base, and the second splicing part is used for being connected with the first splicing part of the adjacent base; the top side surface of the base is used for mounting medical equipment; and the supporting legs are respectively arranged on the base and are used for supporting the base. According to the medical equipment, the supporting structures of the multiple pieces of medical equipment are mutually spliced so that the PET units can be expanded in the axial direction, and the expanding and assembling process of the PET units is simple.

The present invention provides a compound having the structure:and methods of using the compound in targeted PET and SPECT imaging.

The invention discloses a compound represented by the following structural formula (I). Or a pharmaceutically acceptable salt thereof. The variables of Structural Formula (I) are described herein. The compounds of the invention can be attached to chelating groups for radionuclide binding, and thus are suitable for radioimaging and / or radiotherapy applications, for example, the disclosed compounds can be radiolabeled with positron emitters such as 18F, 68Ga or 64Cu, and used for positron emission tomography (PET). Alternatively, the compounds can be radiolabeled with an alpha particle emitter such as 225 Ac, a beta particle emitter such as 67 Cu or 177 Lu or Auger electron emitters (e.g., 111 In, 67 Ga, 99 mTc, 195 mPt, 125 I, and 123 I). The compounds may also be attached to a cytotoxic agent for targeted delivery of the cytotoxic agent to a tumor, such as conjugated to gemcitabine or doxycycline or venom. Likewise, the compound may be conjugated to a compound having a physiological action, such as a TLR agonist, to stimulate the immune response of the receptor.

Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I):wherein R1 is a moiety including a positron emitter; R2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R1 is a moiety including an adamantyl group.

A method may include determining, based on a first positron emission tomography (PET) scan and a first computed tomography (CT) scan from a first timepoint, a first tumor mask corresponding to a first lesion present in the first PET scan and the first CT scan. A second tumor mask corresponding to a second lesion present in the second PET scan and the second CT scan may be determined based on the second PET scan and the second CT scan from a second timepoint. A longitudinal segmentation model may be applied to update, based on the first PET scan, the first CT scan, the second PET scan, and the second CT scan, each of the first tumor mask and the second tumor mask. A response to a treatment for a disease may be determined based on at least one of the first updated tumor mask and the second updated tumor mask. Related systems and computer program products are also provided.

A method may include determining, within a first positron emission tomography and computed tomography (PET-CT) scan depicting a plurality of regions of a body, a first region including a lesion. A first portion of the first PET-CT scan depicting the first region but not a second region of the plurality of regions may be extracted to generate a second PET-CT scan having one or more initial dimensions. The one or more initial dimensions of the second PET-CT scan may be adjusted to one or more target dimensions by at least adding, to the second PET-CT scan, one or more voxels, and determining a value of each of the one or more voxels added to the second PET-CT scan. A segmentation model may be trained based on a training dataset that includes the second PET-CT scan adjusted to the one or more target dimensions.

Positron emission tomography (PET) is a bioimaging technique that relies on positron emitting probes. PET probes can be obtained from a non-labeled probe by a late-stage radiolabelling step with a radionuclide, prior to the injection of the probe to the patient. Because of the short half-life duration of most radionuclides, the radiolabelling step must be rapid. The present invention provides a method allowing the rapid embedding of 68Ga into particles comprising polydopamine. The particles labeled with the method are very stable and are obtained in high yield with a high purity. It has been shown that radiolabeled particles obtained with the method of the invention and functionalized with antibodies were efficient in revealing lung and kidney inflammation via a whole-body PET scan in a LPS-induced sepsis mouse model. Such probes, when they further incorporate magnetic nanoparticles, carry a high potential to improve the diagnosis of inflammation via PET-MRI.

Site-selective conjugation to biomolecules via thiol-based chemistry is superior to the unselective modification of lysine residues, which produce a mixed product and can potentially interfere with binding affinity of the biomolecule. However, in physiological environments, the maleimide-thiol conjugation product which is the current gold-standard for site-selective thiol-conjugation can be susceptible to hydrolysis or a retro-Michael reaction via exchange with reactive thiols such as those in albumin or glutathione residues yet the degradation is relatively slow. Therefore, for in vivo studies, the maleimide-thiol conjugation proposes instability issues. The compositions and methods disclosed herein provide an alternative thiol-based linkage, one that overcomes the instability issues with conventional reagents and methods. The compositions and methods disclosed herein are useful in various contexts, for example, for 18F-labeling of peptides / proteins in the preparation of positron emission tomography (PET) probes.

PET imaging (406) accounts for attenuation by MR hardware (110). A camera (112) captures the MR hardware (110) as positioned on or by the patient (116). For example, MR local coils to be or as positioned between the emission sources in the patient (116) and the PET detector are optically imaged (402). Image processing is used to determine (404) the position of the MR hardware (110). The attenuation of the MR hardware (110) is accounted for in attenuation correction for PET imaging (402) based on the determined position.

The present invention relates to novel, selective, radiolabeled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.